Next Phase Newsletter

The corporate venture capital arm of a multinational engineering company is headquartered in Germany with offices in Israel and the United States. The firm’s investments are focused on financial returns, as well as, bringing strategic value to the parent company. The firm makes equity investments in seed through growth rounds ranging from €1M-€5M for typical investments and may invest up to €10M-€12M over the life of the investment. The firm will lead, co-lead or follow and typically seeks a 10%-25% stake in the company. The firm is currently investing out of its second fund of €150M with a total of €350M AUM, and makes 4-6 investments per year. The firm focuses on North American, European and Israeli companies.

The firm is only interested in diagnostics and monitoring devices with a particular interest in point-of-care diagnostics. Recent investments include an autonomous, mobile robot with delivery tracking software and a PCR-based diagnostic instrument for rapid pathogen detection. The firm does not invest in traditional biopharma therapeutics and/or medical devices which require FDA approval.

The firm will work with all management teams, including first time entrepreneurs, and requires at least an observatory board seat with most investments requiring a standard board seat with voting rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An early-stage investment firm is based in Midwestern US and consists of a team of entrepreneurs experienced in the grind of starting, operating, growing and harvesting exciting companies. The firm is investing from a $23M fund closed in 2014. The firm typically participates in institutional rounds and makes equity investments ranging from $250K-$750K in technology companies in $500K-$2M financing rounds. Convertible notes can be made in less frequent occasions.

Roughly 75% of the businesses the firm looks at are located in the Mountain West, and 25% are outside of the region. The firm seeks to lead a financing round in locally based businesses, but it typically plays a minor role in investment outside of their region unless there is a strong fit and local lead. The firm is currently seeking new opportunities.

Within healthcare, the firm is interested in health technologies that are easy to scale and require a short or no regulatory pathway to market. Examples include genomic analytics, physician-patient interphase platform, mobile health, and medical device with a heavy software component. The firm prefers post-concept projects with recurring revenue of 20-60K/month or some market validation.

The firm is looking for experienced management teams with proven profitability. The firm’s team brings in operational expertise and expects to get involved. The firm is open to both leading and co-investing, and if leading is the case, the firm typically takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An investment group is based in Northeastern United States and invests on behalf of family offices and institutions, and makes direct investments in a variety of sectors including healthcare & life science. Investments in early-stage companies are typically in the form of equity, whereas debt investments in later-stage companies may be considered. The firm’s allocations are highly variable but are generally over $1m, and are typically at least $3m. The firm primarily invests in US-based companies but Canada-based and other international companies may also be considered.

Within the life science sector the firm has diverse interests, with a primary focus on healthcare services companies, including biotech R&D services and healthcare IT services. The firm is also interested in medical devices in late-stage clinical trials, or which are already approved. Investments in therapeutic drug development may be considered but only at later stages (Phase II or later).

The firm seeks to invest in solid management teams who are developing a product based on proprietary, patented technology which addresses a large market need. While the firm may consider investments in pre-revenue companies, they require that a company have a defined path to revenues and will be profitable within three years.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private specialty pharmaceutical company is headquartered in Germany with offices all around the world. The firm’s venture fund focuses on early stage companies, and positions itself to be a strategic corporate partner to develop and support innovative technologies to commercialization in areas for growth opportunity – specifically focused solely in the aesthetics and cosmetics space. The firm currently manages a $30 million (€25 million) fund, and typically makes $1-$5 million investments. The firm is seeking 4-5 investments in early-stage companies, start-ups including spinout companies from academia. The firm is geographically agnostic, and is open to investments from all over the world.

The firm focuses only on aesthetics with an anti-aging focus, including skin rejuvenation and body shaping and modification. The firm is open to all therapeutics, medical devices, and healthcare IT, as long as the technology serves an unmet need/gap in the aesthetic marketplace. The firm has historically invested in injectables, toxins, topicals, cosmetics, and devices. The firm typically looks at seed to early stage companies, and specifically focuses on pre-clinical to clinical stages and pre-concept to concept devices.

As a strategic corporate partner, the firm hopes to bring its own expertise and internal resources to the table. As not only an investor, but also as a strategic partner, the firm anticipates being able to offer advice, support, and consultation for the early-stage company to leverage its global comprehensive network of experts within the firm. The firm offers R&D, clinical, regulatory through to commercial, sales and marketing expertise. The firm believes that providing these services and support to a start-up company is a substantial value-add and will help partnered companies grow and develop with the ability to tap into the firm’s expertise. Thus, the firm will help fill the management team with their global network of internal resources, along with providing all the aforementioned services.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A boutique venture capital firm is based in the Western United States. The firm invests in growth and expansion-stage technology and life science companies. The firm closed its second fund in 2015. The firm prefers to make growth stage investments in Series B, C and D rounds, typically co-investing with other institutional investors. The firm leads about 30% of the investment rounds it takes part in, with allocation sizes varying according to the needs of the round. The firm focuses on companies located in Southern California and other regions underserved by venture capital such as Utah, etc. The firm is actively seeking new investment opportunities, and anticipates that the second fund will invest in over 15 companies.

In the Life Sciences, the firm seeks to invest in diagnostics, therapeutics, and also selectively in medical device opportunities. The firm is opportunistic in terms of subsectors and indications. The firm generally seeks therapeutics that are at least in Phase III and diagnostics and medical devices that are very close to or with FDA approval. The firm historically invested in vitro diagnostic tests and medical imaging.

The firm generally co-invests with top tier institutional investors, and for companies based in Southern California the firm may act as a local lead investor to bring a syndicate together. The firm seeks companies with a strong and experienced management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A specialty pharmaceutical company is headquartered in China with offices in Hong Kong and California. The company focuses on product development and sales and marketing in four therapeutic areas: clinical nutrition, oncology, antibiotics and respiratory system. The company is interested in forming partnerships with biopharmaceutical companies that are interested in entering the Chinese market. The company is flexible in terms of partnering models, which includes in-licensing, co-development, exclusive distribution, joint venture, and product acquisition. The company is actively seeking products from the US and Europe.

The company is currently seeking products in the following therapeutic areas: oncology, respiratory system, antibiotics, clinical nutrition, and cardiovascular. However, the company is equally interested in other areas with unmet medical needs in China (such as CNS, GI, Nephrology, etc). The company will consider both small molecules and biologics. The firm is most interested in NCE or NCE-like molecules. The firm will only consider biosimilar or generics if there are no similar products or very few players with identical chemical/biological structure in China. In terms of phase of development, the firm will consider marketed and early-late clinical stage products for the five listed areas above. For other therapeutic areas, the company is looking for assets that have obtained regulatory approval in the US or Europe markets.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global private equity firm with bases in Hong Kong and the United States is primarily focused on healthcare investments with a particular interest in the life science space. The firm looks to make allocations ranging from $250,000 as the first round in a tranched financing structure to $20 million over the lifetime of the investment and depending on the financial needs of the company. The firm is actively seeking new investments and is open to review opportunities from around the globe.

Within the life science space the firm is interested in therapeutics, medical devices, and diagnostics. The firm is currently most interested in companies with some clinical data however they are open to reviewing pre-clinical stage opportunities as well. The firm is open to biosimilar and repurposed assets, and has a preference for platform technologies but is also open to considering single asset opportunities. The firm is open to review all classes of medical devices and diagnostics. The firm is entirely open in terms of indication.

The firm is open to investing in both private and publically help companies and is currently very interested in making cross over investments. The firm is also very interested in companies that have a plan or ability to enter the Chinese market as the firm can add significant value with this strategy. The firm is open to acting as both a lead and co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com